Antineoplastic Agents, Genital Diseases, Male, Genital Neoplasms, Male, Imatinib, Neoplasms, Abdominal, Prostatic Diseases, Prostatic Neoplasm, Urogenital Neoplasms
Conditions
Keywords
Prostate cancer,, radical prostatectomy,, PSA rise
Brief summary
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
Interventions
DRUGSTI571 (Glivec®)
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* who are 18 years of age or older. * who have undergone radical prostatectomy within 2 years prior to PSA progression . * exhibiting two consecutive rises in PSA levels relative to a previous reference value, separated by 14 days. The first measurement must occur 14 days after the reference value und must be at least 20% above the reference value. The reference value must be at least 0.4 ng/ml. The second confirmatory measurement taken 14 days after the first measurement must be greater than the first measurement. * with a Karnofsky Performance Score (KPS) greater than or equal to 90 (Appendix 5). * with the following hematologic lab values: ANC greater than or equal to 1500/mm3, Hgb greater than or equal to 10g/dL, PLT greater than or equal to 100x109/L. * with the following biochemistry lab values: total bilirubin \< 1.5 ULN, SGOT, SGPT less than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN. * willing to employ an effective barrier method of contraception during the study duration and for 3 months following discontinuation of study drug (for patients of reproductive potential). * with a life expectancy of \> 6 months. * who have provided written informed consent pursuant to local regulatory requirements prior to initiation of any study procedure. with a Gleason Score \> 6 in the prostatectomy specimen
Exclusion criteria
* with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer, unless written approval is obtained by the sponsor. * with prior hormonal therapy * who require therapy with warfarin or analgesics of the morphine class or higher (see Section 3.4.4). * with a known diagnosis of HIV, hepatitis B, or hepatitis C infection. * who have had a major surgery within 2 weeks prior to study entry. * with severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency (NYHA III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease, and active uncontrolled infection. * with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment. | 2 - 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population | continuous |
| investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population. | continuous |
| To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA | continuous |
| To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule. | continuous |
| To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population. | continuous |
Countries
Germany
Outcome results
None listed